Targeted Therapy Targeted Therapies Clinical Trials Cancer Treatment Target Identification Cancer Treatments Senolytics Neuroprotective Agents Neurotherapeutics Molecular Targets Obesity Treatments Gene Therapy Experimental Treatments Alzheimer's Treatments Novel Therapies GSK3-beta Inhibition cGAS-STING Pathway Disease-Modifying Therapies Chronotherapy Neurodegenerative Diseases RNA-targeted Therapies Protein Targeting Protein Therapy Appetite Suppressants Chronic Heart Failure Biological Therapies Immunotherapy FDA Approval Anxiety Treatment Microbiome Considerations Diabetes Treatment Hormonal Therapies Prophylactic Treatments Biologics Metabolic Therapies Tuberculosis Mitochondrial Dysfunction Ferroptosis Neurological Treatments Hormonal Treatments Neuroscience Applications Anti-obesity Treatments Therapeutic Strategies Liver Treatments Preventive Medicine Innovative Therapies Target Engagement NAD+ Augmentation Inflammation Vaccine Development Antioxidants Atherosclerosis Treatment Repurposed Drugs ACLY Inhibitors Preclinical Research Mitochondrial-targeted Therapies Metabolic Disorders Lithium Treatments Clinical Trial Efficiency Anti-fibrotic Drugs Side Effects Anti-inflammatory Drugs Sleep Medications Cell-Based Therapies Nasal Spray Hypoxia Treatments Oligonucleotide Therapy Protein Modulation Compound Screening GPCR Targeting Antivenoms Enzyme Inhibitors Cell Targeting G Protein-Coupled Receptors CAMKK2 Inhibitors CPT Treatment MAOB Inhibitors Psychedelic Research Immune Modulation Cell Movement Manipulation Weight Loss Drugs Genetic Targets NRP1 Inhibitors
Want to see what podcasts are saying about this topic? Search across 130K+ podcasts. Explore Radar
New Nature papers show that blocking the mitochondrial citrate transporter SLC25A1 cuts the acetyl-CoA supply that enables inflammatory gene activation, pointing to a drug strategy to reduce harmful age‑related inflammation.
